

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Currently amended) A method ~~for delivering an anti-target compound to a subject for the treatment of a disorder without being inactivated, by~~ of treating a disorder in a human subject comprising orally administering thereto to the subject a polypeptide ~~construct~~ comprising one or more single domain antibodies, ~~wherein at least one of the single domain antibodies is an anti-TNF-alpha single domain antibody that binds to human TNF-alpha and that comprises CDR 3 of a single domain antibody having the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13 directed against said target.~~
2. (Currently amended) ~~[[A]] The method according to claim 1, wherein the anti-TNF-alpha single domain antibody binds to TNF-alpha said target is located~~ in the gut system.
- 3.-4. (Canceled)
5. (Currently amended) ~~[[A]] The method according to claim 1, wherein the anti-TNF-alpha single domain antibody binds to TNF-alpha said target is located~~ in intestinal mucosa.
- 6.-7. (Canceled)
8. (Currently amended) ~~[[A]] The method according to claim 1, wherein the anti-TNF-alpha single domain antibody binds to TNF-alpha said target is in, or accessible via the blood.~~
- 9.-14. (Canceled)
15. (Currently amended) ~~[[A]] The method according to claim 1, wherein said target is TNF-alpha and the disorder is inflammation.~~

16. (Currently amended) [[A]] ~~The method according to claim 15, wherein the single domain antibody corresponds to a sequence represented by polypeptide comprises any one of SEQ ID NOs: 12 to 14.~~

17.-45. (Canceled)

46. (Currently amended) [[A]] The method according to claim 1, wherein the anti-TNF- α single domain antibodies are antibody is a humanized *Camelidae* VHH[[s]], an homologous sequence of a *Camelidae* VHH amino acid sequence, a functional portion of a *Camelidae* VHH, or a functional portion of an homologous sequence of a *Camelidae* VHH amino acid sequence of the full length single domain antibody, or wherein the polypeptide construct is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length polypeptide construct.

47.-63. (Canceled)

64. (Currently amended) [[A]] The method according to claim 2, wherein said target is located in the stomach or colon.

65.-67. (Canceled)

68. (New) The method according to claim 1, wherein the polypeptide is orally administered to the subject.